Russell Investments Group Ltd. Makes New $3.22 Million Investment in uniQure N.V. $QURE

Russell Investments Group Ltd. purchased a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 303,632 shares of the biotechnology company’s stock, valued at approximately $3,218,000. Russell Investments Group Ltd. owned approximately 0.55% of uniQure at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in QURE. Mraz Amerine & Associates Inc. acquired a new stake in uniQure during the 1st quarter worth approximately $106,000. Wells Fargo & Company MN raised its stake in shares of uniQure by 13.9% during the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 1,503 shares during the last quarter. XTX Topco Ltd lifted its holdings in shares of uniQure by 127.3% during the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 20,720 shares during the period. Bellevue Group AG acquired a new position in shares of uniQure during the fourth quarter worth $397,000. Finally, Lighthouse Investment Partners LLC bought a new stake in shares of uniQure in the fourth quarter worth $397,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Trading Up 1.0%

Shares of QURE stock opened at $15.70 on Friday. uniQure N.V. has a fifty-two week low of $4.45 and a fifty-two week high of $19.18. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. The stock has a 50 day simple moving average of $14.56 and a two-hundred day simple moving average of $13.62. The company has a market cap of $861.46 million, a P/E ratio of -4.01 and a beta of 0.11.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The company had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. Research analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other news, Director David D. Meek sold 2,112 shares of the company’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $30,518.40. Following the transaction, the director owned 34,190 shares in the company, valued at approximately $494,045.50. This represents a 5.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Madhavan Balachandran sold 2,112 shares of the firm’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the sale, the director owned 37,697 shares of the company’s stock, valued at approximately $544,721.65. This represents a 5.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,144 shares of company stock valued at $322,426. 4.79% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on QURE. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Chardan Capital cut their price objective on uniQure from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, July 29th. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 target price on the stock in a report on Thursday, August 14th. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, uniQure currently has an average rating of “Buy” and a consensus price target of $37.45.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.